Gracell Biotechnologies Inc. today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022.
| SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.
Conference call and webcast details: Monday, November 14, 2022 @ 8:00am ET Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days. About Gracell Media contacts Kyle Evans Investor contacts Stephanie Carrington
SOURCE Gracell Biotechnologies Inc. | ||
Company Codes: NASDAQ-NMS:GRCL |
View original content to download multimedia:
